Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment - Seite 2

“This comprehensive sequencing data will also be integrated into the development of large language models (LLMs) and multi-modal artificial intelligence (AI) algorithms to predict cancer risk, detect cancers earlier, and guide intervention. Integration of this genomic data into our longitudinal patient healthcare records in Mayo Clinic Cloud and Mayo Clinic Platform, will facilitate not only the care of each individual patient, but the care of all cancer patients now and in the future,” Dr. Willman added. “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine.”

Patients will consent to have the tests performed and to have the data shared with Mayo Clinic. They will also receive copies of the results for their personal record keeping.

Exact Sciences offers patients and their health care providers access to molecular and genomic data that may provide new insights into the causes of cancers and help researchers develop more effective, personalized treatments for cancer patients.

About Exact Sciences’ Precision Oncology portfolio

Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX Breast Recurrence Score test is recognized as a standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive test of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive molecular tests available to patients today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. The Oncotype DX Breast Recurrence Score test and OncoExTra test were developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory and the OncoExTra test is performed at the Genomic Health Phoenix clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. These tests have not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. To learn more, visit precisiononcology.exactsciences.com.